CD4 and neoplasm: These studies, in addition to previous observations, indicate that agonist 4-1BB antibodies might elicit different responses from CD4 and CD8 T cells, and that the promotion of robust anti-tumor immunity might be a consequence of enhanced CD8 T-cell effector function.